MedPath

A prospective observational study of pembrolizumab and chemotherapy for lung cancer patients with interstitial abnormalities

Not Applicable
Conditions
non-small cell lung cancer
Registration Number
JPRN-UMIN000038594
Lead Sponsor
Kobe University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
2
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with history of drug induced pneumonitis. 2)Patients who has increased infiltration other than lung cancer within 1 month. 3)Patients with interstitial pneumonitis with UIP pattern on computed tomography. 4)Patients with interstitial pneumonitis associated with collagen diseases. 5)Pregnant women and patients who may be pregnant or breastfeeding. 6)Patients who are judged to be inappropriate for the study by the investigator.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath